US

Vaccine Development and Distribution

Question A:

Removing intellectual property protections on Covid-19 vaccines would substantially improve availability of the vaccines in developing countries.

Responses weighted by each expert's confidence

Question B:

Removing intellectual property protections on Covid-19 vaccines would have a negative impact on vaccine development efforts for future variants of SARS-CoV-2 or for the next pandemic.

Responses weighted by each expert's confidence

Question C:

Without an international agreement that facilitates vaccine trade, countries’ incentives to limit exports of vaccines and/or key production inputs are likely to prolong the adverse effects of the pandemic in advanced countries.

Responses weighted by each expert's confidence

Question A Participant Responses

Participant University Vote Confidence Bio/Vote History
Acemoglu
Daron Acemoglu
MIT
Agree
5
Bio/Vote History
Relaxing ex post monopoly after invention helps users, esp. poor users. Sometimes IPR important for market entry but not likely in this case
Altonji
Joseph Altonji
Yale
Uncertain
3
Bio/Vote History
Auerbach
Alan Auerbach
Berkeley
Agree
5
Bio/Vote History
Autor
David Autor
MIT
Agree
4
Bio/Vote History
Baicker
Katherine Baicker
University of Chicago
Uncertain
3
Bio/Vote History
Banerjee
Abhijit Banerjee
MIT
Strongly Agree
6
Bio/Vote History
Bertrand
Marianne Bertrand
Chicago
Uncertain
4
Bio/Vote History
Brunnermeier
Markus Brunnermeier
Princeton Did Not Answer Bio/Vote History
Chetty
Raj Chetty
Harvard Did Not Answer Bio/Vote History
Chevalier
Judith Chevalier
Yale
Disagree
6
Bio/Vote History
With 10-12 vaccines, many w/strong commitments to license to anyone, other supply chain issues seem to be a stronger impediment.
Cutler
David Cutler
Harvard
Uncertain
4
Bio/Vote History
Deaton
Angus Deaton
Princeton
Agree
8
Bio/Vote History
But this does NOT mean that it is good policy, especially without qualifications.
Duffie
Darrell Duffie
Stanford
Agree
2
Bio/Vote History
My "agree" does not imply that I think this is a good idea. But if the cost of an already developed product is cut, take-up will increase.
Edlin
Aaron Edlin
Berkeley
Agree
6
Bio/Vote History
Sharing know-how is also important.
Eichengreen
Barry Eichengreen
Berkeley
Agree
5
Bio/Vote History
Einav
Liran Einav
Stanford
Strongly Agree
1
Bio/Vote History
Fair
Ray Fair
Yale
Disagree
5
Bio/Vote History
Finkelstein
Amy Finkelstein
MIT
Disagree
3
Bio/Vote History
Goldberg
Pinelopi Goldberg
Yale
Disagree
9
Bio/Vote History
It is politics, not IPR: extremely stringent criteria for borrowing for vaccines designed to exclude Russian, India and Chinese vaccines
Goolsbee
Austan Goolsbee
Chicago
Strongly Agree
8
Bio/Vote History
Greenstone
Michael Greenstone
University of Chicago
Strongly Agree
7
Bio/Vote History
Hall
Robert Hall
Stanford
Uncertain
2
Bio/Vote History
Outside my area of expertise. I believe vaccines are currently sold to those countries at below full market prices.
Hart
Oliver Hart
Harvard
Strongly Agree
8
Bio/Vote History
Holmström
Bengt Holmström
MIT
Uncertain
3
Bio/Vote History
Hoxby
Caroline Hoxby
Stanford
No Opinion
Bio/Vote History
There is a large expert literature on this topic.I am not one of the experts so I would ask a few of them rather than give an amateur answer
Hoynes
Hilary Hoynes
Berkeley
Uncertain
8
Bio/Vote History
Given the need for herd immunity globally, I suspect that vaccines will be available worldwide without this change.
Judd
Kenneth Judd
Stanford
Uncertain
7
Bio/Vote History
Firms need IP to recover R&D costs but the high prices should be applied only to sales in developed countries with others paying at most MC.
Kaplan
Steven Kaplan
Chicago Booth
Uncertain
8
Bio/Vote History
Kashyap
Anil Kashyap
Chicago Booth
Uncertain
3
Bio/Vote History
see all the other roadblocks listed in question c, not clear whether this alone would move the dial
Klenow
Pete Klenow
Stanford
Agree
3
Bio/Vote History
Levin
Jonathan Levin
Stanford
Uncertain
1
Bio/Vote History
Perhaps, but not sure it works better than subsidizing purchases or investments in capacity.
Maskin
Eric Maskin
Harvard
Agree
7
Bio/Vote History
Nordhaus
William Nordhaus
Yale
Agree
4
Bio/Vote History
Removing all or for low-income markets? Yes for latter.
Obstfeld
Maurice Obstfeld
Berkeley
Disagree
8
Bio/Vote History
Vaccines are notoriously complex to manufacture and regulate, as evidence from the COVID-19 pandemic has made clear. See ch 3 in PDF below.
-see background information here
Saez
Emmanuel Saez
Berkeley
Disagree
5
Bio/Vote History
Samuelson
Larry Samuelson
Yale
Agree
8
Bio/Vote History
There may be effective interventions less drastic than simply removing protection, but some intervention would enhance availability.
Scheinkman
José Scheinkman
Columbia University
Uncertain
4
Bio/Vote History
Initial increase may not be substantial given the many licensing agreements already in existence.
Schmalensee
Richard Schmalensee
MIT
Uncertain
5
Bio/Vote History
I don't know if shortages of know-how, production facilities, or critical inputs would prevent expansion of production.
Shapiro
Carl Shapiro
Berkeley
Strongly Agree
8
Bio/Vote History
Shimer
Robert Shimer
University of Chicago
Agree
3
Bio/Vote History
Stock
James Stock
Harvard
Agree
4
Bio/Vote History
Thaler
Richard Thaler
Chicago Booth
Uncertain
1
Bio/Vote History
Not sure about "substantially" because the drug companies will (eventually) permit generics for the rest of the world.
Udry
Christopher Udry
Northwestern
Agree
6
Bio/Vote History
Not sure about "substantially", especially in relevant time frame. Need more than this, because even marginal cost pricing is too high.

Question B Participant Responses

Participant University Vote Confidence Bio/Vote History
Acemoglu
Daron Acemoglu
MIT
Uncertain
6
Bio/Vote History
Drug innovation respond to profits (see links). But there is plenty of profits from rich nations; those from LDCs won't to be decisive.
-see background information here
Altonji
Joseph Altonji
Yale
Agree
3
Bio/Vote History
Auerbach
Alan Auerbach
Berkeley
Strongly Agree
7
Bio/Vote History
Autor
David Autor
MIT
Agree
5
Bio/Vote History
New equilibrium: If governments lift vaccineIP protections ex post, they should be prepared to pay for the next round of vaccines ex ante.
Baicker
Katherine Baicker
University of Chicago
Strongly Agree
3
Bio/Vote History
Banerjee
Abhijit Banerjee
MIT
Uncertain
5
Bio/Vote History
The answer depends on how this is done. It could be a relatively cheap buy out--the developers have made enough money already from the OECD.
Bertrand
Marianne Bertrand
Chicago
Uncertain
5
Bio/Vote History
Brunnermeier
Markus Brunnermeier
Princeton Did Not Answer Bio/Vote History
Chetty
Raj Chetty
Harvard Did Not Answer Bio/Vote History
Chevalier
Judith Chevalier
Yale
Agree
6
Bio/Vote History
Details matter but a change in the rules that makes it harder for companies to recoup investments in variant development, etc. problematic
Cutler
David Cutler
Harvard
Agree
4
Bio/Vote History
Depends if in all countries or just low income countries.
Deaton
Angus Deaton
Princeton
Agree
7
Bio/Vote History
Negative indicates sign, no more. And again, everything is in how it is done.
Duffie
Darrell Duffie
Stanford
Strongly Agree
2
Bio/Vote History
Edlin
Aaron Edlin
Berkeley
Agree
6
Bio/Vote History
Compensation could limit or eliminate any negative impact.
Eichengreen
Barry Eichengreen
Berkeley
Agree
5
Bio/Vote History
Einav
Liran Einav
Stanford
Disagree
1
Bio/Vote History
Fair
Ray Fair
Yale
Agree
5
Bio/Vote History
Finkelstein
Amy Finkelstein
MIT
Agree
3
Bio/Vote History
Goldberg
Pinelopi Goldberg
Yale
Agree
8
Bio/Vote History
Goolsbee
Austan Goolsbee
Chicago
Uncertain
1
Bio/Vote History
Without any compensation for taking it away you mean?
Greenstone
Michael Greenstone
University of Chicago
Agree
2
Bio/Vote History
Hall
Robert Hall
Stanford
Agree
2
Bio/Vote History
Some economists have proposed to avoid this issue through government buyouts of IP rights.
Hart
Oliver Hart
Harvard
Agree
7
Bio/Vote History
Holmström
Bengt Holmström
MIT
Uncertain
3
Bio/Vote History
Hoxby
Caroline Hoxby
Stanford
Strongly Agree
10
Bio/Vote History
Removing IP protection is not a method of internalizing externalities that comes out of economics (public goods) theory.We have smarter ways
Hoynes
Hilary Hoynes
Berkeley
Uncertain
8
Bio/Vote History
Judd
Kenneth Judd
Stanford
Agree
7
Bio/Vote History
Kaplan
Steven Kaplan
Chicago Booth
Strongly Agree
10
Bio/Vote History
Kashyap
Anil Kashyap
Chicago Booth
Agree
3
Bio/Vote History
Look at Pfizer's share price since the start of the pandemic, even with success and current regime it has not gained that much
Klenow
Pete Klenow
Stanford
Uncertain
2
Bio/Vote History
Levin
Jonathan Levin
Stanford
Agree
4
Bio/Vote History
Maskin
Eric Maskin
Harvard
Agree
7
Bio/Vote History
Nordhaus
William Nordhaus
Yale
Uncertain
5
Bio/Vote History
Same point as above.
Obstfeld
Maurice Obstfeld
Berkeley
Agree
8
Bio/Vote History
Saez
Emmanuel Saez
Berkeley
Uncertain
4
Bio/Vote History
Samuelson
Larry Samuelson
Yale
Disagree
6
Bio/Vote History
This vaccine received massive government support, and such support could ensure future development despite protection compromises.
Scheinkman
José Scheinkman
Columbia University
Agree
7
Bio/Vote History
Unless governments can coordinate and institute appropriate prizes, which in the case of vaccines are probably superior to IP protection.
-see background information here
Schmalensee
Richard Schmalensee
MIT
Strongly Agree
7
Bio/Vote History
Shapiro
Carl Shapiro
Berkeley
Uncertain
3
Bio/Vote History
Depends. Lucrative contracts to supply vaccines to rich countries with no impediments to sales in other countries could work very well.
Shimer
Robert Shimer
University of Chicago
Strongly Agree
7
Bio/Vote History
Stock
James Stock
Harvard
Strongly Agree
4
Bio/Vote History
Thaler
Richard Thaler
Chicago Booth
Agree
5
Bio/Vote History
It all depends on when you do it. I am all for setting up prizes for vaccine and other drugs. We have to let them make some money.
Udry
Christopher Udry
Northwestern
Strongly Disagree
7
Bio/Vote History
Incentivizing pandemic-context vaccine development via expected monopoly profits from patent protection is insane. Public investment needed.
-see background information here
-see background information here

Question C Participant Responses

Participant University Vote Confidence Bio/Vote History
Acemoglu
Daron Acemoglu
MIT
Strongly Agree
6
Bio/Vote History
Global cooperation is key for a global pandemic. If half of the world does not vaccinate, new mutants will emerge and spread in the West too
-see background information here
Altonji
Joseph Altonji
Yale
Agree
5
Bio/Vote History
Auerbach
Alan Auerbach
Berkeley
Agree
3
Bio/Vote History
Autor
David Autor
MIT
Agree
4
Bio/Vote History
Baicker
Katherine Baicker
University of Chicago
Uncertain
3
Bio/Vote History
Banerjee
Abhijit Banerjee
MIT
Agree
7
Bio/Vote History
Bertrand
Marianne Bertrand
Chicago
Agree
5
Bio/Vote History
Brunnermeier
Markus Brunnermeier
Princeton Did Not Answer Bio/Vote History
Chetty
Raj Chetty
Harvard Did Not Answer Bio/Vote History
Chevalier
Judith Chevalier
Yale
Agree
2
Bio/Vote History
Low certainty here as details matter.
Cutler
David Cutler
Harvard
Agree
7
Bio/Vote History
Deaton
Angus Deaton
Princeton
Agree
6
Bio/Vote History
Lots of ways of writing such an agreement, and not doing so is hardly a real possibility.
Duffie
Darrell Duffie
Stanford
Strongly Agree
1
Bio/Vote History
Edlin
Aaron Edlin
Berkeley
Agree
3
Bio/Vote History
Uncertain now how big a problem this is. Potentially big.
Eichengreen
Barry Eichengreen
Berkeley
Agree
5
Bio/Vote History
Einav
Liran Einav
Stanford
Agree
1
Bio/Vote History
Fair
Ray Fair
Yale
Agree
5
Bio/Vote History
Finkelstein
Amy Finkelstein
MIT
Uncertain
3
Bio/Vote History
Goldberg
Pinelopi Goldberg
Yale
Disagree
8
Bio/Vote History
It's too late for int. agreem. and it would not be enforceable anyway. By end of 2021 there will be enough production capacity for everyone
Goolsbee
Austan Goolsbee
Chicago
Strongly Agree
5
Bio/Vote History
Greenstone
Michael Greenstone
University of Chicago
Uncertain
2
Bio/Vote History
Hall
Robert Hall
Stanford
Uncertain
2
Bio/Vote History
This question seems to presuppose that individual countries have market power in the world market for vaccines, which is not obvious
Hart
Oliver Hart
Harvard
Agree
7
Bio/Vote History
Holmström
Bengt Holmström
MIT
Agree
6
Bio/Vote History
Hoxby
Caroline Hoxby
Stanford
No Opinion
Bio/Vote History
Question is just too vague for me to answer. Details of trade agreements matter.
Hoynes
Hilary Hoynes
Berkeley
Agree
8
Bio/Vote History
Risk aversion and own country preference would seem a big obstical.
Judd
Kenneth Judd
Stanford
Agree
7
Bio/Vote History
Increasing returns to scale imply that coordination and cooperation can be far more effective than individual national programs.
Kaplan
Steven Kaplan
Chicago Booth
Uncertain
3
Bio/Vote History
Kashyap
Anil Kashyap
Chicago Booth
Agree
3
Bio/Vote History
far from my expertise, but this seems like an own goal. if the virus is alive in developing countries how does normality elsewhere prevail?
Klenow
Pete Klenow
Stanford
Agree
2
Bio/Vote History
Levin
Jonathan Levin
Stanford
Uncertain
4
Bio/Vote History
Maskin
Eric Maskin
Harvard
Agree
5
Bio/Vote History
Nordhaus
William Nordhaus
Yale
Strongly Agree
7
Bio/Vote History
Obstfeld
Maurice Obstfeld
Berkeley
Strongly Agree
9
Bio/Vote History
See ch 10 by Bown and Bollyky in the Peterson Institute Briefing issued today, URL below. We need an international vaccine treaty.
-see background information here
Saez
Emmanuel Saez
Berkeley
Agree
7
Bio/Vote History
Samuelson
Larry Samuelson
Yale
Agree
6
Bio/Vote History
Advanced countries are safe from the virus only when the entire world is safe.
Scheinkman
José Scheinkman
Columbia University
Agree
7
Bio/Vote History
Schmalensee
Richard Schmalensee
MIT
Agree
4
Bio/Vote History
Shapiro
Carl Shapiro
Berkeley
Uncertain
4
Bio/Vote History
Shimer
Robert Shimer
University of Chicago
Disagree
5
Bio/Vote History
Stock
James Stock
Harvard
Uncertain
4
Bio/Vote History
Thaler
Richard Thaler
Chicago Booth
Agree
1
Bio/Vote History
Udry
Christopher Udry
Northwestern
Strongly Agree
9
Bio/Vote History